Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263673 | 1.00 | MCHR1 (0.67) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| Hydrochloric Acid SCHEMBL4258579 | 0.99 | MCHR1 (0.66) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| Hydrochloric Acid SCHEMBL4258575 | 0.99 | MCHR1 (0.66) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| SCHEMBL4263661 | 0.87 | MCHR1 (0.69) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| SCHEMBL4263667 | 0.87 | MCHR1 (0.69) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| Hydrochloric Acid SCHEMBL4257335 | 0.86 | MCHR1 (0.67) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| Hydrochloric Acid SCHEMBL4257343 | 0.86 | MCHR1 (0.67) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| SCHEMBL4266951 | 0.86 | MCHR1 (0.74) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| SCHEMBL4266945 | 0.86 | MCHR1 (0.74) | MCHR1ADRA2AADRA1AHRH1HTR2B | |
| Hydrochloric Acid SCHEMBL4269849 | 0.85 | MCHR1 (0.73) | MCHR1ADRA2AADRA1AHRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1730122-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | MCHR1 3/4885ADRA2A 178/4885ADRA1A 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.